Ultivue

?? Reminder: Join Vizgen at the Society for Immunotherapy of Cancer (SITC) 2024 for our symposium presentation with Nimbus Therapeutics on Saturday, Nov. 9 at 12:30 pm in Room 320C. Nimbus will share new research findings and a case study demonstrating how our ultrasensitive InSituPlex? assays and the STARVUE? AI-driven image analysis platform are validating their clinical prognosis and accelerating drug development. Nimbus will also present new data from their Phase 1/2 clinical trial of an HPK1 inhibitor for treatment of advanced solid tumors. Symposium Presentation Details: Title: “Evaluating Treatment Efficacy and Tumor Immune Contexture with InSituPlex? and STARVUE? Technologies” Presenters: Scott Daigle, Sr. Director of Translational Medicine at Nimbus Therapeutics, and Angela Vasaturo, Director of Scientific Affairs at Vizgen Vizgen scientists will also present three posters demonstrating the capabilities of the company’s portfolio of leading spatial biology solutions for advancing immunotherapy research. ?? Details: https://hubs.ly/Q02Xw4D50 We look forward to seeing you there!

"Vizgen cemented its leadership spot among private spatial biology companies on October 9, when it announced a merger with Ultivue."? We couldn't agree more! We’re excited to share that Vizgen has once again been named Genetic Engineering & Biotechnology News’ #1 private spatial biology company —an exciting milestone on the heels of the Vizgen-Ultivue merger. Through the combination of Vizgen’s strengths in single-cell spatial genomics and Ultivue’s leadership in multiplex proteomic profiling, we’re now uniquely equipped to deliver a unified spatial multi-omics solution to our customers, opening new doors for researchers and helping to unlock new opportunities for innovation in discovery and clinical development.?Here’s to pushing the boundaries of what’s possible in spatial biology! Read more in GEN:?https://lnkd.in/gNMTn6_M

??Join Vizgen, recently merged with Ultivue, at Society for Immunotherapy of Cancer (SITC) 2024 to explore new breakthroughs in spatial biology for immunotherapy.? We’re looking forward to presenting new research findings and a case study with?Nimbus Therapeutics demonstrating?how Nimbus utilizes ultrasensitive InSituPlex? assays and the STARVUE? AI-driven image analysis platform to validate their clinical prognosis and accelerate drug development. ??See new data from Nimbus’ Phase 1/2 clinical trial of an HPK1 inhibitor for treatment of advanced solid tumors. ??Learn?how InSituPlex? reduces assay development times, streamlining the path from validation to results. ??Explore?high-precision biomarker detection in action, enabling robust and actionable insights through deep-learning models. ???Symposium Presentation: Saturday, Nov. 9, 2024?| 12:30–1:30 p.m.?|?Room 320 C “Evaluating Treatment Efficacy and Tumor Immune Contexture with InSituPlex? and STARVUE? Technologies” Presenters:? Scott Daigle, Sr Director of Translational Medicine, Nimbus Therapeutics Angela Vasaturo, Director of Scientific Affairs, Vizgen? Vizgen scientists will also present three posters demonstrating the capabilities of the company’s portfolio of leading spatial biology solutions.? Details on each presentation are below and here: https://hubs.ly/Q02W7mfZ0 We hope to see you at SITC!

Join us at the Spatial Biology for Drug Development Summit to discover how OmniVUE? modular biomarker panels accelerate precision oncology research with flexible panel assembly for rapid and agile investigation of tumor spatial biology. On October 23 at 1:45pm ET, Yvette Cajigas will present: “Demonstrating Robustness and Phenotypic Diversity with OmniVUE?: A Customizable Multiplex Immunofluorescence Platform.” Learn how the OmniVUE? modular multiplex panels help reduce assay development timelines from months to weeks with our continuously expanding core library of more than 24 validated, clinically relevant biomarkers for clinical-grade assay performance and barcode amplification. Yvette will also demonstrate how our InSituPlex? assays’ proprietary signal amplification delivers more insights from a single slide while visualizing up to 12 biomarkers simultaneously–including T-cell, macrophage and tumor markers–with unprecedented consistency and high dynamic range. See how the platform detects complex tumor phenotypes from a single sample so that precious specimens can be preserved for future analyses. We hope to see you there! Reach out to us to schedule a meeting via our website or email us at [email protected].

“The combined company—which will carry the Vizgen name—will build upon its namesake predecessor’s expertise in single-cell spatial genomics and Ultivue’s leadership in multiplex proteomic profiling. The new Vizgen also aims to increase its presence in clinical lab settings while continuing to serve customers in research institutions and biopharmas.” In Genetic Engineering & Biotechnology News, learn more about what this week’s Ultivue-Vizgen merger means for the field of spatial multi-omics and the future of precision medicine: https://hubs.ly/Q02T1r3y0

Today’s an exciting day for Ultivue as we announce our merger with Vizgen. By combining Ultivue’s market-leading multiplex proteomic biomarker detection and advanced AI-driven spatial tissue profiling with Vizgen’s deep expertise in single-cell spatial genomics, we are now uniquely positioned to unlock new potential in spatial multi-omics, accelerate discovery and clinical development, and drive future breakthroughs that improve human health. Rob Carson, formerly CEO of Ultivue, will become the President and CEO of the newly combined Vizgen. Learn more about the merger and what’s to come: https://hubs.ly/Q02SKNGp0 #SpatialBiology #MultiOmics

We hope to see you at the 2nd Annual MarketsandMarkets ImmunoBio Series. Discover how our AI-powered spatial biology tools for exploring the tumor microenvironment deliver quantitative, high confidence insights in just a fraction of the time of conventional methods. On October 15 at 10:00 am CEST, Angela Vasaturo, Director of Scientific Affairs at Ultivue, will present: “Ultrasensitive ISP assays for high quality spatial insights.” ??See how Ultivue’s ultrasensitive InSituPlex? assays capture an unprecedented view into the vast complexity of cellular interactions within the tumor microenvironment and enable researchers to localize biomarkers directly within tissue. ??Learn how InSituPlex technology enhances understanding of spatial tissue biology at scale, reducing biomarker-based analytic cycle times by more than 70% and accelerating the drug development process. ??Angela will also share new data demonstrating how the technology’s proprietary signal amplification enables biomarker detection with significantly higher sensitivity, compared to alternate approaches. We hope to see you there! #Spatialbiology #cancerresearch

This clip from our recent webinar with Adaptimmune shows how researchers used Ultivue InSituPlex? multiplex immunofluorescence (mIF) technology to immunophenotype biopsy samples from both responders and non-responders in a clinical trial of a T-cell therapy drug. Whole-slide mIF staining enabled the visualization and quantification of infiltrating activated engineered T-cells and their co-localization with tumor and immune cells, with higher quantitative evidence of activated states in responder patients. Learn more about the use of mIF in spatial analysis of the tumor microenvironment in our free webinar: https://hubs.ly/Q02N62Kg0 #SpatialBiology #Multiplex #mIF #ImmuneProfiling #ImmunoOncology #ImageAnalysis #TumorMicroenvironment #Biomarkers #BiomarkerDiscovery #InSituPlex #OmniVUE

Check out our latest case study, which demonstrates the successful use of Ultivue's InSituPlex? technology to visualize therapeutic response biomarkers in an immunotherapy Phase 1/2 clinical trial. Researchers at Nimbus Therapeutics evaluated pre- and post-treatment patient biopsy samples using a multiplex immunofluorescence (mIF) assay and a custom 12-plex U-VUE? panel. Ultivue assays enabled: ? Identification of Potential Immunotherapy Biomarkers: Ultivue's InSituPlex? technology facilitated the identification of potential biomarkers associated with positive treatment response. ? Comprehensive Immune Profiling: The custom 12-plex U-VUE? panel enabled a deep analysis of the tumor microenvironment, providing insights into the cellular composition, functional state, and spatial organization of immune cells in response to treatment. ? Validation of Mechanism of Action: The findings from the mIF analysis provided crucial evidence supporting the proposed mechanism of the therapeutic. Read the case study here: https://hubs.ly/Q02NPFFM0 #SpatialBiology #Multiplex #mIF #ImmuneProfiling #ImmunoOncology #ImageAnalysis #TumorMicroenvironment #Biomarkers #BiomarkerDiscovery #ClinicalTrials #Immunotherapy #InSituPlex #UVUE

Researchers at Adaptimmune conduct extensive pre- and post-treatment tissue profiling in their clinical trials to understand the effectiveness of their cell-based therapies. In this clip from our recent webinar, Adaptimmune researchers explain how they used Ultivue’s InSituPlex? multiplex immunofluorescence (mIF) technology to select discrete regions of interest within biopsy samples for comparative transcriptomic analysis between treatment responders and non-responders. Watch the full webinar to learn what they found: https://hubs.ly/Q02N61Hs0 #SpatialBiology #Multiplex #mIF #ImmuneProfiling #ImmunoOncology #ImageAnalysis #TumorMicroenvironment #Biomarkers #BiomarkerDiscovery #InSituPlex #OmniVUE